📋 Key Information Summary
- Bronchiectasis is defined by permanent abnormal bronchial dilatation on HRCT (broncho-arterial ratio >1, or lack of tapering within 2 cm of pleural surface), with a rising prevalence in Australia, particularly among Aboriginal and Torres Strait Islander peoples.
- Key aetiologies include post-infectious (childhood adenovirus, pertussis, measles, TB), idiopathic (≈30–40%), COPD overlap, cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and immunodeficiency (IgG subclass deficiency, CVID).
- All patients require sputum microscopy, culture and sensitivity (MC&S) at baseline and during every exacerbation; Pseudomonas aeruginosa colonisation is the single most important prognostic marker.
- Airway clearance is the cornerstone of chronic management — active cycle of breathing technique (ACBT), oscillating PEP devices, and autogenic drainage; chest physiotherapy referral is essential.
- Mucoactive agents: hypertonic saline (7%) nebulised, mannitol dry powder (Bronchitol® PBS-listed), and mucolytics (N-acetylcysteine) improve mucus clearance and quality of life.
- Long-term macrolide prophylaxis (azithromycin 500 mg Mon/Wed/Fri or 250 mg daily) reduces exacerbation frequency by ~50% — monitor ECG for QTc, liver function, and audiometry; confirm sputum NTM-negative before initiation.
- Acute exacerbations: treat with 14 days of antibiotics guided by prior sputum culture; first-line oral amoxicillin 500 mg–1 g TDS or doxycycline 200 mg then 100 mg daily if Haemophilus influenzae/atypical suspected.
- Pseudomonal exacerbations require ciprofloxacin 750 mg PO BD or IV anti-pseudomonal β-lactam (piperacillin-tazobactam, ceftazidime, or meropenem) for 14 days; consider inhaled tobramycin (300 mg BD) or aztreonam lysine for chronic colonisation.
- Hemoptysis — minor: oral tranexamic acid 1 g TDS; major/life-threatening: interventional radiology for bronchial artery embolisation (BAE); surgical resection reserved for localised disease refractory to embolisation.
- Complications include respiratory failure (home oxygen assessment), pulmonary hypertension/cor pulmonale (echocardiography screening), and rarely amyloidosis; pneumococcal and influenza vaccination are mandatory.
- Aboriginal and Torres Strait Islander peoples have the highest prevalence of bronchiectasis globally (up to 1,470/100,000 children in Top End communities); early childhood infection, overcrowding, and limited access to specialist care drive disease burden.
- Refer to respiratory specialist for all newly diagnosed cases, suspected CF/PCD/immunodeficiency, frequent exacerbations (≥3/year), chronic Pseudomonas colonisation, hemoptysis, or consideration of surgical resection.
Introduction & Australian Epidemiology
Bronchiectasis is a chronic respiratory condition characterised by permanent, pathological dilatation of the bronchi resulting from cycles of airway inflammation, infection, and impaired mucociliary clearance. Once considered an "orphan disease," bronchiectasis is increasingly recognised as a significant cause of chronic respiratory morbidity in Australia, with rising hospitalisation rates and healthcare utilisation over the past two decades.
The Australian Bronchiectasis Registry (ABR), established in 2015 through the Lung Foundation Australia, has provided crucial data on disease burden, aetiology, and outcomes in the Australian population. Current estimates suggest a prevalence of approximately 500–700 per 100,000 adults in the general Australian population, though this is likely an underestimate given under-diagnosis in primary care.
Health inequity: Aboriginal and Torres Strait Islander children in remote Northern Territory communities have a bronchiectasis prevalence of up to 1,470 per 100,000 — among the highest reported globally. Non-CF bronchiectasis is a leading cause of chronic lung disease in Indigenous Australian children.
The disease exhibits a bimodal age distribution: a paediatric peak (often post-infectious, frequently resolving with growth) and an adult peak (predominantly idiopathic, post-infectious, or associated with COPD). Female sex predominates in adult-onset idiopathic bronchiectasis. The economic burden is substantial, with direct healthcare costs estimated at >$10,000 per patient per annum, driven largely by hospitalisations for acute exacerbations.
Key Australian Statistics
- Hospital separations for bronchiectasis (non-CF) have increased by ~30% over the past decade (AIHW data).
- Median age at diagnosis in adults: 60–65 years; in children: 4–6 years.
- ~40% of adult cases are classified as idiopathic after thorough investigation.
- Chronic Pseudomonas aeruginosa colonisation is present in 15–30% of Australian adult patients and is associated with faster FEV₁ decline and increased mortality.
- Indigenous Australians with bronchiectasis present earlier, have more severe disease, higher rates of Pseudomonas colonisation, and worse outcomes than non-Indigenous Australians.
Diagnosis & Aetiology
HRCT Diagnostic Criteria
High-resolution computed tomography (HRCT) of the chest is the gold standard for diagnosing bronchiectasis. Scans should be performed at full inspiration (1 mm collimation, 10 mm intervals) and, where available, expiratory images should be obtained to identify air trapping and small airway disease.
| HRCT Sign | Description | Sensitivity |
|---|---|---|
| Broncho-arterial ratio >1 | Internal bronchial diameter exceeds accompanying pulmonary artery diameter — the hallmark sign | High (most specific) |
| Lack of tapering | Bronchi fail to taper normally within 2 cm of the pleural surface or visualised bronchus extends to the pleural margin | High |
| Signet ring sign | Dilated bronchus seen in cross-section adjacent to a smaller pulmonary artery — resembles a signet ring | Moderate |
| Tram-track sign | Parallel thickened bronchial walls seen in longitudinal section (cylindrical bronchiectasis) | Moderate |
| Mucus plugging | Bronchial filling with mucus, often finger-in-glove pattern | Variable |
MBS Item 56806 / 56810: CT chest is rebatable under Medicare. HRCT should specifically be requested (not standard contrast CT) for bronchiectasis assessment. Specify "HRCT chest for bronchiectasis evaluation" on the referral to ensure appropriate protocol.
HRCT Morphological Classification (Reid Classification)
| Type | Morphology | Characteristics |
|---|---|---|
| Cylindrical (varicose) | Smooth, uniform dilatation | Most common type; parallel walls, mild disease |
| Varicose | Beaded, irregular dilatation | Intermediate severity; areas of narrowing and dilation |
| Cystic | Grape-like clusters of dilated airways | Most severe; often associated with Pseudomonas colonisation |
Aetiology — Systematic Workup
An identifiable cause can be found in 60–70% of cases. A structured aetiological workup is recommended for all newly diagnosed patients, guided by clinical phenotype and severity.
| Aetiology | Proportion | Key Features & Investigations |
|---|---|---|
| Idiopathic | 30–40% | Diagnosis of exclusion; female predominance; often lower lobe predominant |
| Post-infectious | 25–30% | Childhood adenovirus, pertussis, measles, RSV, TB, non-tuberculous mycobacteria (NTM); history of severe childhood pneumonia |
| COPD overlap | 10–15% | Smoking history, concurrent emphysema, COPD phenotype; CT bronchiectasis + emphysema |
| Allergic bronchopulmonary aspergillosis (ABPA) | 2–5% | Central bronchiectasis, eosinophilia, elevated total IgE >1,000 IU/mL, positive Aspergillus-specific IgE/IgG, serum precipitins |
| Cystic fibrosis (CF) | Separate entity | Sweat chloride test (MBS 11900), CFTR genotyping; upper lobe predominant; sinus disease; pancreatic insufficiency |
| Primary ciliary dyskinesia (PCD) | 2–5% | Situs inversus (50%), neonatal respiratory distress, chronic rhinositis, infertility; nasal NO screening, ciliary biopsy (electron microscopy), genetic testing |
| Immunodeficiency | 5–10% | CVID, IgG subclass deficiency; measure serum IgG, IgA, IgM, IgG subclasses, functional antibody responses (pre/post pneumococcal vaccine titres) |
| NTM infection | 5–10% | M. avium complex (MAC), M. abscessus; Lady Windermere syndrome (right middle lobe/lingula); requires sputum AFB cultures ×3, NTM PCR |
| Rheumatoid arthritis | 2–3% | Pre- or post-RA onset; may be worsened by methotrexate or anti-TNF therapy |
Recommended Aetiological Investigations
Essential
Sputum MC&S, AFB, fungal culture
At baseline and every exacerbation; sputum for NTM if clinical/radiological suspicion
Essential
Spirometry with bronchodilator response (MBS 11505)
Baseline and annually; pattern may be obstructive, mixed, or occasionally restrictive
Essential
Full blood count, eosinophils, total IgE, Aspergillus-specific IgE/IgG
Screen for ABPA and eosinophilic airway disease
Essential
Serum immunoglobulins (IgG, IgA, IgM, IgG subclasses)
Screen for immunodeficiency; if low IgG, check pneumococcal vaccine response
Available
Sweat chloride / CFTR genotyping
Consider in all patients <40 years, upper lobe disease, recurrent pancreatitis, or atypical features — refer to CF centre
Available
Nasal nitric oxide (nNO)
Screening for PCD; low nNO (<77 nL/min adults) warrants referral for ciliary studies
Referral
Ciliary biopsy / electron microscopy / genetic panel
Referral to specialised PCD centre (Royal Children's Hospital Melbourne, Westmead Children's Hospital)
Chronic Management
Chronic management of bronchiectasis is centred on four pillars: airway clearance, mucoactive therapy, infection prevention/treatment, and management of underlying causes. A multidisciplinary approach involving respiratory physicians, physiotherapists, pharmacists, and dietitians is recommended.
Airway Clearance Techniques
Airway clearance is the single most important intervention in bronchiectasis management. All patients should be referred to a respiratory physiotherapist for individualised assessment and technique prescription.
1
Active Cycle of Breathing Technique (ACBT)
Comprises breathing control, thoracic expansion exercises, and forced expiratory technique (huffing). First-line for most patients. Duration: 20–30 minutes, 1–2 times daily.
2
Oscillating Positive Expiratory Pressure (PEP)
Devices include Acapella®, Flutter®, Aerobika®. Oscillation helps loosen mucus from airway walls. Particularly useful for patients who struggle with ACBT alone. Available on state equipment schemes.
3
Autogenic Drainage
Three-phase breathing technique at different lung volumes to mobilise peripheral to central mucus. Requires specialist physiotherapy instruction. Useful in CF and severe bronchiectasis.
4
Postural Drainage
Gravity-assisted positioning to drain affected lobes. Use HRCT to guide positioning. Modified positions (semi-recumbent, 15° head-down tilt) preferred in elderly or those with reflux.
5
Manually Assisted Techniques
Percussion and vibrations performed by physiotherapist or trained carer. Increasingly replaced by mechanical devices but remain useful when equipment unavailable in remote settings.
Mucoactive Agents
Hypertonic Saline (7% NaCl)
Mucomyst® nebuliser solution · Osmotic hydrator
Adult dose
4 mL of 7% NaCl nebulised BD via jet nebuliser; pre-treat with SABA (e.g., salbutamol 200–400 mcg) to prevent bronchospasm
Paediatric dose
3–4 mL of 3% NaCl nebulised BD for children <6 years; 7% NaCl may be used in children ≥6 years with SABA pre-treatment
Key notes
Improves mucus clearance and reduces exacerbation frequency; first-line mucoactive therapy in non-CF bronchiectasis
PBS status
✔ PBS General Benefit
Mannitol (inhaled dry powder)
Bronchitol® · Osmotic agent
Adult dose
400 mg inhaled BD via proprietary dry powder inhaler; initial dose titration and bronchial provocation test required
Key notes
Indicated for non-CF bronchiectasis; improves quality of life and sputum weight; requires bronchial challenge testing prior to initiation
PBS status
⚠ PBS Authority Required — must be initiated by or on advice of a respiratory physician
N-Acetylcysteine (NAC)
Fluimucil® · Mucomyst® · Mucolytic
Adult dose
600 mg PO daily or BD; can also be nebulised (3 mL of 20% solution BD)
Key notes
Thins mucus by breaking disulphide bonds; limited RCT evidence in non-CF bronchiectasis; generally well tolerated; may cause GI upset
PBS status
✔ PBS General Benefit (oral formulation)
Bronchodilators
Bronchodilators are not disease-modifying in bronchiectasis but are indicated when there is coexistent airflow obstruction (reversible or fixed) or significant dyspnoea. Always assess response objectively with spirometry.
Salbutamol
Ventolin® · SABA
Adult dose
200–400 mcg MDI ± spacer PRN (up to 8 puffs/day); or 2.5–5 mg nebulised BD–QID
Paediatric dose
100–200 mcg MDI ± spacer PRN; or 2.5 mg nebulised BD
PBS status
✔ PBS General Benefit
Tiotropium
Spiriva® · LAMA
Adult dose
18 mcg inhaled OD via HandiHaler®; or tiotropium/olodaterol (Respimat®) 2.5/5 mcg OD for combined obstruction
Key notes
Use when FEV₁ <80% predicted with documented bronchodilator response or significant breathlessness despite airway clearance
PBS status
⚠ PBS Authority Required
Anti-Inflammatory Therapy
Chronic airway inflammation is a hallmark of bronchiectasis. While inhaled corticosteroids (ICS) are not routinely recommended for bronchiectasis in the absence of asthma or COPD overlap, macrolide antibiotics have anti-inflammatory and immunomodulatory properties and are used as long-term prophylaxis in frequent exacerbators (see Exacerbation Management section).
ICS caution: Routine use of inhaled corticosteroids in bronchiectasis without coexistent asthma or COPD is not recommended. ICS may increase the risk of NTM infection and pneumonia. If prescribed for coexistent asthma/COPD, monitor sputum cultures closely and consider concurrent macrolide prophylaxis.
Inhaled corticosteroids may be considered in the following scenarios:
- Coexistent asthma with documented eosinophilic inflammation (FeNO >40 ppb or blood eosinophils >300 cells/μL)
- COPD overlap with frequent exacerbations despite LABA/LAMA
- ABPA: systemic corticosteroids (prednisolone 0.5 mg/kg/day for 2 weeks, then taper over 6–8 weeks) + itraconazole 200 mg BD (PBS Authority Required)
Vaccination & Preventive Care
- Influenza vaccine: Annual (free under NIP for all Australians with chronic respiratory disease)
- Pneumococcal vaccine: Pneumococcal conjugate (PCV13 or PCV20) followed by pneumococcal polysaccharide (PPSV23) at ≥8-week interval — funded under NIP for at-risk groups
- COVID-19: Annual booster recommended (chronic respiratory condition — priority group)
- Pertussis booster: dTpa every 10 years if not recently received
- Smoking cessation: Absolute requirement; offer NRT, varenicline (Champix®), or bupropion (Zyban®); referral to Quitline (13 7848)
Exacerbation Management
A bronchiectasis exacerbation is defined as a sustained deterioration (≥48 hours) in at least three of the following symptoms beyond normal day-to-day variation: cough, sputum volume, sputum purulence, breathlessness, exercise tolerance, fatigue, or hemoptysis. Exacerbations drive disease progression, accelerate lung function decline, and reduce quality of life.
Hospital admission criteria: Consider inpatient management for severe breathlessness, respiratory failure (SpO₂ <92% on air), significant hemoptysis, systemic sepsis, failed outpatient oral therapy, or social factors precluding home management.
Sputum Culture — Essential in Every Exacerbation
Sputum MC&S should be collected before initiating antibiotics whenever feasible. If sputum is difficult to obtain, consider hypertonic saline nebulisation induction. Patients with known chronic colonisation may be started on antibiotics based on prior culture results, but a fresh specimen should still be sent.
Essential
Sputum microscopy, culture & sensitivity (MC&S)
Request for routine bacteria AND specify "mycobacterial culture" if NTM suspected; request fungal culture if ABPA suspected
Essential
Sputum for acid-fast bacilli (AFB) / NTM PCR
At least 3 specimens on separate days if NTM is suspected; early morning specimens preferred
Available
Chest X-ray (CXR)
May show new infiltrates, mucus plugging; useful for excluding pneumonia but HRCT preferred for bronchiectasis assessment
Antibiotic Selection — Exacerbations
Antibiotic duration for bronchiectasis exacerbations is typically 14 days — longer than for acute COPD exacerbations (5–7 days) due to the higher bacterial burden and biofilm formation within dilated airways. Antibiotic choice should be guided by the most recent sputum culture result.
Mild–Moderate
Outpatient Oral Therapy
Sputum purulence increase ± mild breathlessness; stable vitals; SpO₂ ≥94% on air; able to manage at home
Setting: Outpatient / GP
Moderate–Severe
Oral or IV Therapy
Significant breathlessness, sputum volume increase, constitutional symptoms, failing initial oral therapy
Setting: Hospital / specialist review
Severe / Life-threatening
IV Therapy + Supportive Care
Respiratory failure, haemodynamic instability, extensive disease, Pseudomonas sepsis
Setting: Hospital admission ± HDU/ICU
| Scenario | First-Line Antibiotic | Duration | PBS Status |
|---|---|---|---|
| No prior isolate / H. influenzae | Amoxicillin 500 mg–1 g PO TDS | 14 days | PBS General Benefit |
| Penicillin allergy / atypical organisms | Doxycycline 200 mg day 1 then 100 mg PO daily | 14 days | PBS General Benefit |
| Moraxella catarrhalis | Amoxicillin-clavulanate 875/125 mg PO BD | 14 days | PBS General Benefit |
| Pseudomonas aeruginosa (mild–moderate) | Ciprofloxacin 750 mg PO BD | 14 days | PBS General Benefit |
| Pseudomonas (severe / resistant / failing oral) | Piperacillin-tazobactam 4.5 g IV TDS or Ceftazidime 2 g IV TDS or Meropenem 1 g IV TDS | 14 days (IV then consider oral step-down) | Hospital PBS |
| MRSA | Vancomycin IV (target trough 15–20 mg/L) or linezolid 600 mg PO/IV BD | 14 days | Hospital PBS |
Inhaled Antibiotics — Chronic Pseudomonas Colonisation
For patients with chronic Pseudomonas aeruginosa colonisation (≥3 positive cultures in 12 months) and frequent exacerbations (≥3/year), long-term inhaled antibiotic therapy should be considered. These agents achieve high intrapulmonary concentrations with minimal systemic absorption.
Tobramycin (inhaled)
TOBI® 300 mg/5 mL nebuliser solution · Aminoglycoside
Adult dose
300 mg nebulised BD via jet nebuliser (e.g., Pari LC Plus® or eFlow®); 28 days on / 28 days off cycling regimen
Key notes
Reduces Pseudomonas density, exacerbation frequency, and improves quality of life; pre-treat with SABA; monitor audiometry and renal function every 6 months
PBS status
⚠ PBS Authority Required — non-CF bronchiectasis with chronic Pseudomonas colonisation, ≥3 exacerbations/year
Aztreonam lysine (inhaled)
Cayston® 75 mg powder for nebulisation · Monobactam
Adult dose
75 mg nebulised TDS via Altera® eFlow nebuliser; 28 days on / 28 days off cycling; used as alternative to tobramycin or in combination cycling
Key notes
Alternative inhaled anti-pseudomonal agent; may be used in patients intolerant of tobramycin or with tobramycin-resistant Pseudomonas; requires specific nebuliser device
PBS status
⚠ PBS Authority Required — for chronic Pseudomonas colonisation in non-CF bronchiectasis
Macrolide Prophylaxis
Long-term macrolide therapy is the most evidence-based intervention for reducing exacerbation frequency in bronchiectasis. The landmark BAT (Bronchiectasis and Long-Term Azithromycin Treatment), EMBRACE, and BAT-2 trials demonstrated a ~50% reduction in exacerbations. The mechanism involves both anti-inflammatory (neutrophilic) and anti-biofilm effects, in addition to antimicrobial activity against H. influenzae and atypical organisms.
Azithromycin
Zithromax® · Macrolide
Adult dose — preferred regimen
500 mg PO Monday, Wednesday, Friday (three times weekly); OR 250 mg PO daily
Paediatric dose
5 mg/kg/day (max 250 mg) PO three times weekly for children ≥6 years; use weight-based dosing below this
Duration
Minimum 6–12 months; reassess at 12 months for ongoing benefit; many patients require indefinite therapy
Renal adjustment
No adjustment required for mild–moderate impairment; caution in severe renal impairment (eGFR <15 mL/min)
Key monitoring
ECG (QTc) at baseline and 1 month; LFTs at 3 months then 6-monthly; sputum NTM culture before initiation; audiometry if symptoms
PBS status
⚠ PBS Authority Required — non-CF bronchiectasis, ≥3 exacerbations/year despite optimal airway clearance
Before starting macrolide prophylaxis: (1) Confirm sputum is negative for NTM (MAC, M. abscessus) — macrolide monotherapy promotes macrolide-resistant NTM. (2) Check baseline ECG for QTc prolongation (avoid if QTc >450 ms male / >470 ms female). (3) Review for drug interactions (statins, warfarin, digoxin, colchicine). (4) Document hearing baseline. (5) Ensure up-to-date pneumococcal vaccination.
Complications
Hemoptysis Management
Hemoptysis occurs in 20–50% of bronchiectasis patients and ranges from blood-streaked sputum to life-threatening massive hemoptysis. Bronchiectasis is one of the most common causes of non-massive hemoptysis in Australia.
| Severity | Definition | Initial Management | Escalation |
|---|---|---|---|
| Blood-streaked sputum | Streaks of blood in sputum; <20 mL/day | Reassure; review and optimise airway clearance; rule out coagulopathy; ensure not on excessive anticoagulation | If recurrent, refer to respiratory physician for HRCT review |
| Mild–moderate hemoptysis | 20–200 mL/24 hr | Tranexamic acid 1 g PO/IV TDS (antifibrinolytic); correct coagulopathy; monitor haemoglobin; respiratory physician review | If not settling in 48 hr, consider CT pulmonary angiography and referral for bronchial artery embolisation |
| Major / life-threatening hemoptysis | >200 mL/24 hr or haemodynamic instability | Emergency: Secure airway (affected side down, intubation if needed), IV access, cross-match blood, IV tranexamic acid 1 g stat, resuscitation | Urgent bronchial artery embolisation (BAE) by interventional radiology — first-line definitive treatment; success rate 85–95% |
Tranexamic Acid
Cyklokapron® · Antifibrinolytic
Adult dose — oral
1 g PO TDS for 5–7 days or until hemoptysis resolves
Adult dose — IV
1 g IV over 10 minutes TDS; for massive hemoptysis give 1 g IV stat immediately
Key cautions
Avoid in DIC, active thromboembolic disease; caution with concurrent hormonal contraception; discontinue if visual disturbance
PBS status
✔ PBS General Benefit
Massive hemoptysis — call 000: Any hemoptysis >200 mL/24 hr or any hemoptysis causing haemodynamic compromise is a medical emergency. Position affected side down, secure large-bore IV access, cross-match blood, give IV tranexamic acid 1 g stat, and arrange urgent transfer to a centre with interventional radiology for bronchial artery embolisation.
Respiratory Failure
Progressive bronchiectasis can lead to chronic respiratory failure, typically Type II (hypoxic + hypercapnic), particularly in advanced disease with extensive bilateral involvement. Assessment follows standard COPD/respiratory failure pathways.
- Pulse oximetry: SpO₂ target 88–92% in patients at risk of hypercapnia; arrange arterial blood gas (ABG) if SpO₂ <92% or clinically suspected Type II failure.
- Long-term oxygen therapy (LTOT): Indicated if PaO₂ ≤55 mmHg (or ≤59 mmHg with cor pulmonale/polycythaemia) — assess via ABG on room air, confirmed on two occasions ≥3 weeks apart. Funded under state-based Home Oxygen Programs.
- Non-invasive ventilation (NIV): Consider for chronic hypercapnic respiratory failure (PaCO₂ >50 mmHg) with recurrent admissions, particularly if comorbid obstructive sleep apnoea (overlap syndrome). Refer for sleep study and NIV titration.
- Pulmonary rehabilitation: Evidence-based improvement in exercise capacity and quality of life; available at major hospitals and community health centres. Funded under Medicare for chronic respiratory disease.
Cor Pulmonale & Pulmonary Hypertension
Pulmonary hypertension secondary to chronic hypoxia occurs in advanced bronchiectasis. Clinical features include progressive dyspnoea, peripheral oedema, raised JVP, loud P₂, and right ventricular heave.
Essential
Transthoracic echocardiography
Screen for pulmonary hypertension (estimated RVSP >40 mmHg) and right ventricular dilatation/dysfunction; perform if FEV₁ <50% predicted or clinical features of cor pulmonale
Essential
NT-proBNP / BNP
Elevated levels support right heart failure; useful for monitoring treatment response
Referral
Right heart catheterisation
Definitive diagnosis of pulmonary hypertension; referral to pulmonary hypertension centre (e.g., Alfred Hospital Melbourne, Royal Adelaide Hospital) if echo suggests significant PH
Management of cor pulmonale in bronchiectasis focuses on optimising the underlying lung disease (airway clearance, infection control, oxygen therapy), salt/fluid restriction, and diuretics (furosemide 20–40 mg PO daily, spironolactone 25–50 mg PO daily). Specific pulmonary vasodilator therapy is generally not indicated and requires specialist PH centre management.
Surgical Resection — Indications
Surgical resection for bronchiectasis has become less common with improvements in medical management but remains an important option in selected patients with localised disease.
1
Localised Disease
Bronchiectasis confined to a single lobe or segment (typically left lower lobe or right middle lobe) unresponsive to ≥12 months of optimal medical therapy
2
Refractory Hemoptysis
Recurrent major hemoptysis localised to one area not amenable to or failing bronchial artery embolisation
3
Recurrent Focal Infections
Repeated infections (including abscess formation) in the same lobe despite aggressive medical therapy
4
Adequate Pulmonary Reserve
Pre-operative FEV₁ >1.5 L (or >40% predicted); V/Q scan to estimate post-operative lung function; multidisciplinary thoracic surgical conference discussion
Lung transplant referral: Consider referral for lung transplantation assessment in patients with progressive disease despite maximal medical therapy, FEV₁ <30% predicted, recurrent life-threatening hemoptysis, respiratory failure requiring chronic NIV, or poor quality of life. Referral to the Alfred Hospital (Melbourne), St Vincent's Hospital (Sydney), or Princess Alexandra Hospital (Brisbane) transplant programmes.
Special Populations
Paediatrics
Diagnosis: HRCT is gold standard but requires sedation/general anaesthesia in young children; low threshold for CT when chronic wet cough (>4 weeks) fails to respond to 2 courses of antibiotics.
Aetiology workup: Prioritise CF (sweat test), immunodeficiency (IgG subclasses), and PCD (nasal NO) in all paediatric cases; post-infectious is most common cause in Indigenous children.
Airway clearance: Age-appropriate techniques — bubble PEP in toddlers, oscillating PEP devices from age 4+, supervised ACBT from age 6+; physiotherapy every 3–6 months.
Antibiotics: Amoxicillin 45 mg/kg/day TDS (max 3 g/day) for exacerbations; 14-day courses; 3-monthly sputum cultures during stable periods.
Macrolide prophylaxis: Azithromycin 5 mg/kg (max 250 mg) Mon/Wed/Fri for frequent exacerbators ≥6 years; monitor growth.
Prognosis: Paediatric post-infectious bronchiectasis may partially or completely resolve with growth, particularly if treated aggressively with airway clearance and infection control. Serial HRCT may show improvement in some children.
Pregnancy
Pre-conception: Optimise lung function, ensure up-to-date sputum culture, maximise airway clearance, and review medications — cease teratogenic agents (ciprofloxacin, tetracyclines).
Safe antibiotics: Amoxicillin, amoxicillin-clavulanate, cephalosporins, and azithromycin are safe in pregnancy. Avoid ciprofloxacin (cartilage toxicity), doxycycline (tooth discolouration after 1st trimester), and co-trimoxazole (folate antagonism in 1st trimester).
Mucoactive agents: Hypertonic saline nebulisation is safe; mannitol (Bronchitol®) — limited pregnancy data, use with caution; NAC — avoid in first trimester unless essential.
Monitoring: Increase review frequency to monthly; monitor SpO₂; FEV₁ may normally decline slightly in 3rd trimester — interpret with respiratory physician input.
Delivery: Vaginal delivery preferred; epidural analgesia reduces breathlessness during labour; avoid prolonged supine positioning; optimise sputum clearance before delivery.
Breastfeeding is encouraged. Continue airway clearance and compatible antibiotics during lactation.
Elderly (>65 years)
Overlap with COPD: Many elderly bronchiectasis patients have coexistent COPD; bronchiectasis-COPD overlap syndrome (BCOS) is associated with more exacerbations, worse lung function, and higher mortality than either condition alone.
Airway clearance: Physical limitations may restrict technique options; prioritise oscillating PEP devices (Acapella®) and modified postural drainage; home physiotherapy visits via My Aged Care referral.
Antibiotic considerations: Renal dose adjustment required for many agents; increased risk of C. difficile with prolonged courses; consider probiotic co-administration.
Macrolide caution: Higher QTc prolongation risk; baseline and follow-up ECG essential; review polypharmacy interactions (statins, warfarin, digoxin).
Screen for aspiration — oesophageal dysmotility and reflux are common contributors to bronchiectasis in the elderly. Consider modified barium swallow if recurrent aspiration suspected.
Renal Impairment
Dose adjustments: Ciprofloxacin — reduce to 500 mg BD (eGFR 30–50), 500 mg daily (eGFR <30); Cotrimoxazole — reduce by 50% if eGFR 15–30; Aminoglycosides (IV) — extended interval dosing guided by therapeutic drug monitoring.
Tranexamic acid: Dose reduction required in renal impairment (eGFR 20–60: reduce to 50% dose; eGFR <20: avoid or use with extreme caution — risk of accumulation and seizures).
Macrolides: Azithromycin does not require dose adjustment; however, increased risk of QTc prolongation in dialysis patients — mandatory ECG monitoring.
Many antibiotics used in bronchiectasis are renally cleared; always check eGFR before prescribing.
Hepatic Impairment
Key cautions: Ciprofloxacin and amoxicillin-clavulanate — hepatotoxicity risk; monitor LFTs. Azithromycin — rare cholestatic hepatitis; baseline and periodic LFT monitoring.
Coagulopathy: Patients with hepatic impairment may have coagulopathy, increasing hemoptysis risk and complicating tranexamic acid use; check INR before antifibrinolytic therapy.
Cirrhosis patients with bronchiectasis have increased infection risk due to immune dysfunction — lower threshold for antibiotic therapy.
Immunocompromised
Primary immunodeficiency: CVID and IgG subclass deficiency are important treatable causes; IV immunoglobulin (IVIg) replacement reduces infection frequency — refer to clinical immunologist.
Secondary immunosuppression: Patients on biologics (anti-TNF, rituximab), chemotherapy, or post-transplant have increased risk of unusual pathogens — broaden sputum culture requests to include NTM, fungi, and consider Nocardia.
NTM risk: Immunosuppressed patients are at increased NTM infection risk; macrolide monotherapy must be avoided (promotes resistance); ensure combination NTM therapy if colonised.
Patients on immunosuppressive therapy for rheumatoid arthritis with bronchiectasis require careful monitoring — methotrexate and anti-TNF agents may exacerbate bronchiectasis.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
Bronchiectasis is a disease of profound health inequity for Aboriginal and Torres Strait Islander Australians. Indigenous children in remote communities of the Northern Territory, Far North Queensland, and Western Australia have among the highest prevalence rates of non-CF bronchiectasis documented anywhere in the world. The burden of disease reflects the cumulative impact of early childhood respiratory infections, environmental factors, socioeconomic disadvantage, and healthcare access barriers.
Critical health gap: Aboriginal and Torres Strait Islander children are hospitalised for bronchiectasis at 8–12 times the rate of non-Indigenous Australian children. Median age at diagnosis is significantly younger (2–4 years vs 4–6 years). Chronic Pseudomonas aeruginosa colonisation develops earlier and is more prevalent, driving accelerated lung function decline.
Key Risk Factors in Indigenous Communities
- Early childhood infections: High rates of severe lower respiratory tract infections in infancy (RSV, adenovirus, Streptococcus pneumoniae, Haemophilus influenzae) — often inadequately treated due to access delays.
- Environmental tobacco smoke: Smoking rates among Aboriginal and Torres Strait Islander adults remain ~40% (vs ~10% non-Indigenous); passive smoke exposure significantly increases childhood respiratory infection severity.
- Overcrowded housing: Persistent overcrowding in remote communities facilitates respiratory pathogen transmission; the Australian Government's National Partnership on Remote Housing aims to address this but progress remains slow.
- Malnutrition: Protein-energy malnutrition and micronutrient deficiencies (vitamin D, zinc) impair immune function and are associated with more severe childhood respiratory infections.
- Healthcare access: Remote communities rely on Aboriginal Community Controlled Health Organisations (ACCHOs) and visiting specialist services; specialist respiratory review may require medical evacuation to regional centres (Alice Springs, Darwin, Cairns, Townsville).
Culturally Responsive Care
Key Organisations & Resources
- Lung Foundation Australia — Indigenous Lung Health: Culturally tailored resources for bronchiectasis education and management.
- RHDAustralia (Menzies School of Health Research): Evidence-based guidelines for chronic lung disease in remote Indigenous communities.
- Australian Indigenous HealthInfoNet: Summaries and resources on respiratory health for Aboriginal and Torres Strait Islander peoples.
- NACCHO (National Aboriginal Community Controlled Health Organisation): Advocacy and support for ACCHOs delivering respiratory care.
- CARPA Clinical Procedures Manual: Primary care guidelines for remote Aboriginal health services, including bronchiectasis management.
Quick Reference — Exacerbation Antibiotic Guide
No prior isolate / empiric
Amoxicillin 500 mg–1 g PO TDS
14 days
Or doxycycline 200 mg day 1 then 100 mg daily if penicillin allergy
H. influenzae
Amoxicillin 1 g PO TDS
14 days
Add β-lactamase inhibitor (amox-clav) if β-lactamase positive
Moraxella catarrhalis
Amox-clav 875/125 mg PO BD
14 days
Doxy or cipro as alternative
P. aeruginosa — oral
Ciprofloxacin 750 mg PO BD
14 days
Check culture sensitivity; may need IV if resistant
P. aeruginosa — IV
Piptaz 4.5 g IV TDS or Ceftaz 2 g IV TDS
14 days
Consider adding IV tobramycin for severe infection
MRSA
Vancomycin IV (trough 15–20) or Linezolid 600 mg PO/IV BD
14 days
Infectious disease consult recommended
NTM (MAC)
Azithro 500 mg + Ethambutol 15 mg/kg + Rifampicin 450–600 mg
12+ months (sputum conversion)
Three-times-weekly regimen; ID/respiratory specialist initiation
Monitoring & Follow-Up
Regular monitoring is essential to detect disease progression, colonising organisms, treatment complications, and the impact of management interventions. The following schedule is recommended for stable bronchiectasis patients managed in primary care with respiratory physician co-management.
| Assessment | Frequency | Details |
|---|---|---|
| Respiratory physician review | 3–6-monthly (stable); sooner if frequent exacerbations | Symptom review, management optimisation, vaccination status |
| Spirometry (MBS 11505) | 6–12-monthly | FEV₁, FVC, bronchodilator response; track trajectory |
| Sputum MC&S | 3-monthly during stability + every exacerbation | Track colonisation status; detect Pseudomonas acquisition |
| HRCT chest | Not routinely repeated; clinical deterioration or new symptoms | Baseline HRCT sufficient for most; repeat if concern for progression, NTM, or new focal abnormality |
| Quality of life (QoL-B or Leicester Cough Questionnaire) | 6–12-monthly | Validated disease-specific tools; monitor treatment response |
| Exercise capacity (6MWT) | Annually or as clinically indicated | Functional assessment; guide pulmonary rehabilitation referral |
| Echocardiography | If FEV₁ <50% predicted or clinical features of cor pulmonale | Screen for pulmonary hypertension and RV dysfunction |
| ECG (if on macrolide) | Baseline, 1 month, then annually | QTc monitoring; discontinue macrolide if QTc >500 ms |
| Audiometry (if on macrolide/tobramycin) | Baseline, 6-monthly for inhaled tobramycin | Detect ototoxicity; prompt dose adjustment or cessation |
| Renal function (if on aminoglycosides) | Monthly during active treatment | eGFR, creatinine; electrolytes if on diuretics |
Annual review checklist: Vaccination status, sputum colonisation trend, spirometry trajectory, exacerbation frequency, medication review (ongoing need for macrolide, inhaled antibiotics, mucoactive agents), oxygen assessment, psychological wellbeing (anxiety/depression screening), and advance care planning for advanced disease.
📚 References
- 1. Chang AB, Bell SC, Byrnes CA, et al. Thoracic Society of Australia and New Zealand (TSANZ) position statement: chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Respirology. 2010;15(5):739–753.
- 2. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–i58.
- 3. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
- 4. Goyal V, Grimwood K, Marchant J, et al. Does failed chronic wet cough response to antibiotics predict bronchiectasis? Arch Dis Child. 2014;99(6):522–525.
- 5. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660–667.
- 6. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–1259.
- 7. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–1267.
- 8. Chang AB, Upham JW, Masters IB, et al. Protracted bacterial bronchitis: the last decade and the road ahead. Pediatr Pulmonol. 2016;51(3):225–242.
- 9. Singleton RJ, Valery PC, Morris P, et al. Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol. 2014;49(2):189–200.
- 10. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Respiratory disease. Canberra: AIHW; 2023.
- 11. Lung Foundation Australia. Australian Bronchiectasis Registry: Annual Report 2022–2023. Milton, QLD: Lung Foundation Australia; 2023.
- 12. Chalmers JD, McDonnell MJ, Rutherford R, et al. The generalised bronchiectasis severity index and responsiveness to treatment: international multicentre cohort study. Eur Respir J. 2016;48(3):683–693.
- 13. Murray MP, Turnbull K, MacQuarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J. 2009;33(2):312–318.
- 14. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014;69(12):1073–1079.
- 15. McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016;71(12):1110–1118.
- 16. National Aboriginal Community Controlled Health Organisation (NACCHO). National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait Islander People. 3rd ed. Melbourne: RACGP/NACCHO; 2018.